Welcome to the real world Matthew Gordon examines the differences between observational studies and phase III clinical trials(more)
Drug regulation: still room for improvement The Medicines Act is 40 years old this year, but regulations and regulators have to change to keep up with rapid changes in medicines and society, says Les Rose.(more)
Quality not quantity for pharmacists Wednesday, September 15, 2004
The new pharmacy contract will reward quality services rather than volume of prescriptions, requiring a change in mindset from pharmacists and patients....(more)
When good medicine goes bad Thursday , September 09, 2004
This year the MHRA will start mandatory pharmacovigilance inspections that could affect everyone from the designated qualified person to the sales representative in the field....(more)
Rethinking the supply chain Friday , September 03, 2004
Successful pharma companies in the past excelled at drug development and marketing but one of the keys to success in the future could be excellent manufacturing and supply chain management....(more)
New technology in clinical trials Thursday , September 02, 2004
Tearing up the paper-based approach to clinical trials could save the pharma industry time and money and there are a number of different technologies available....(more)
OTC statins: lifesaver or lifestyle? Wednesday, September 01, 2004
Patients, the government or pharmaceutical companies: who will benefit from over-the-counter statin sales and will the health service be the ultimate loser?...(more)
The future of brand launches Wednesday, September 01, 2004
Expectations for new products are high but, with lifecycles getting shorter, what are the key trends being predicted for the pharma industry's new brand launches?...(more)
